Market Cap 133.38M
Revenue (ttm) 70,000.00
Net Income (ttm) -84.95M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -121,357.14%
Debt to Equity Ratio 0.00
Volume 1,698,800
Avg Vol 3,764,566
Day's Range N/A - N/A
Shares Out 103.40M
Stochastic %K 73%
Beta 1.52
Analysts Strong Sell
Price Target $3.17

Company Profile

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses SynCon, to help engineer precisely designed plasmid DNA plasmids, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company's lead product candidate is INO-3107 for HPV-...

Industry: Biotechnology
Sector: Healthcare
Phone: 267 440 4200
Address:
660 West Germantown Pike, Suite 110, Plymouth Meeting, United States
wallstbullinfinity
wallstbullinfinity Aug. 31 at 9:15 AM
$INO collaborations with the Dana-Farber Cancer Institute and Mass General Brigham to evaluate cadonilimab in combination with INOVIO's DNA medicine INO-5412 in glioblastoma (GBM). 🧬🧬🧬🌍🌎🌏 Akeso, Inc | Akeso 2026 Interim Results: Strong Commercialization Momentum; IO2.0+ Global Strategy Redefining Clinical Standards; Bispecific Advancement in ADC, I&I and Alzheimer's https://share.google/v2oC0mQ88fZZlPmO2
0 · Reply
wallstbullinfinity
wallstbullinfinity Aug. 31 at 9:06 AM
$INO HONG KONG, Aug. 27, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced its 2026 interim results. During the reporting period, the Company achieved record-high drug sales revenue Cadonilimab is advancing multi-pathway combination strategies, including combinations with small molecules such as axitinib and tinengotinib in renal and liver cancers, as well as collaborations with the Dana-Farber Cancer Institute and Mass General Brigham to evaluate cadonilimab in combination with INOVIO's DNA medicine INO-5412 in glioblastoma (GBM). Akeso 2026 Interim Results: Strong Commercialization Momentum; IO2.0+ Global Strategy Redefining Clinical Standards; Bispecific Advancement in ADC, I&I and Alzheimer's https://share.google/FmJF1YgA7L2mWCN13
0 · Reply
FZFund
FZFund Aug. 30 at 7:43 PM
$INO if this falls to $1.08 I am going all in!
1 · Reply
updownsides
updownsides Aug. 30 at 7:24 PM
$INO If by some miracle 3107 gets approved, get used to the word "Step Therapy." Probably not an issue until whoever buys them for pennies and does a phase 3 after bankruptcy. https://youtu.be/WYxUrNtLRvw?is=9c7FKwNfc4fKbgLb
0 · Reply
updownsides
updownsides Aug. 30 at 7:08 PM
$INO Buttley the shameless pumper has never given accurate information. The fact he still thinks VGX-3100 will be approved this year when there hasn't been a readout let alone a submission shows his grip on reality is lost. Now it's Geneos. From the 10-Q; As of March 31, 2026 and December 31, 2025, the Company held approximately 9% and 23%, respectively, of the outstanding equity interests of Geneos on an as-converted to common stock basis. The decrease in the Company's ownership interest during the three months ended March 31, 2026 resulted from the issuance of preferred equity securities by Geneos to third-party investors during the first quarter of 2026, in which the Company did not participate. Due to Geneos' continuing net losses, the carrying value of the Company’s investment in Geneos was $0 as of March 31, 2026. N-I-N-E P-E-R-C-E-N-T and not valued anymore in rhe 10-Q!!
0 · Reply
BentleyT99
BentleyT99 Aug. 30 at 4:53 PM
1 · Reply
sunny3
sunny3 Aug. 30 at 11:14 AM
0 · Reply
sunny3
sunny3 Aug. 29 at 12:44 PM
$INO Feel Great
0 · Reply
Whateverbro
Whateverbro Aug. 29 at 1:13 AM
$INO Its running right into resistance on the weekly and on the daily wait for it to break that the more times it try to push up the more chance of a break . Any one know of any up coming news whats the pipeline, why you bullish
3 · Reply
PumperBoatGuy
PumperBoatGuy Aug. 29 at 1:04 AM
$INO ebola keeps spreading into largest ebola outbreak ever. INO has an ebola vaccine sitting on the shelf.
0 · Reply
Latest News on INO
Inovio reports Q2 EPS (7c) vs. (61c) last year

2026-08-17T08:46:43.000Z - 14 days ago

Inovio reports Q2 EPS (7c) vs. (61c) last year


Inovio upgraded to Buy from Hold at Jefferies

2026-08-17T08:33:04.000Z - 14 days ago

Inovio upgraded to Buy from Hold at Jefferies


Inovio Pharmaceuticals Earnings Call Transcript: Q2 2026

Aug 12, 2026, 4:30 PM EDT - 18 days ago

Inovio Pharmaceuticals Earnings Call Transcript: Q2 2026


Inovio Pharmaceuticals Quarterly report: Q2 2026

Aug 12, 2026, 4:30 PM EDT - 18 days ago

Inovio Pharmaceuticals Quarterly report: Q2 2026


Inovio Pharmaceuticals Earnings release: Q2 2026

Aug 12, 2026, 4:30 PM EDT - 18 days ago

Inovio Pharmaceuticals Earnings release: Q2 2026


Inovio Pharmaceuticals Slides: Q2 2026

Aug 12, 2026, 4:30 PM EDT - 18 days ago

Inovio Pharmaceuticals Slides: Q2 2026


Inovio price target lowered to $4 from $6 at Piper Sandler

2026-08-03T11:36:30.000Z - 27 days ago

Inovio price target lowered to $4 from $6 at Piper Sandler


INOVIO Announces Pricing of $20.0 Million Public Offering

Jul 29, 2026, 8:53 PM EDT - 4 weeks ago

INOVIO Announces Pricing of $20.0 Million Public Offering


INOVIO Announces Proposed Public Offering

Jul 29, 2026, 4:01 PM EDT - 4 weeks ago

INOVIO Announces Proposed Public Offering


Inovio files $300M mixed securities shelf

2026-07-02T20:05:10.000Z - 2 months ago

Inovio files $300M mixed securities shelf


Inovio Pharmaceuticals Slides: Corporate presentation

Jun 5, 2026, 7:00 AM EDT - 3 months ago

Inovio Pharmaceuticals Slides: Corporate presentation


Inovio price target lowered to $2.50 from $3 at H.C. Wainwright

2026-06-01T10:38:41.000Z - 3 months ago

Inovio price target lowered to $2.50 from $3 at H.C. Wainwright


Inovio Pharmaceuticals Transcript: AGM 2026

May 20, 2026, 9:00 AM EDT - 3 months ago

Inovio Pharmaceuticals Transcript: AGM 2026


Inovio Pharmaceuticals Earnings Call Transcript: Q1 2026

May 13, 2026, 4:30 PM EDT - 3 months ago

Inovio Pharmaceuticals Earnings Call Transcript: Q1 2026


Inovio Pharmaceuticals Quarterly report: Q1 2026

May 13, 2026, 4:30 PM EDT - 3 months ago

Inovio Pharmaceuticals Quarterly report: Q1 2026


Inovio Pharmaceuticals Earnings release: Q1 2026

May 13, 2026, 4:30 PM EDT - 3 months ago

Inovio Pharmaceuticals Earnings release: Q1 2026


Inovio Pharmaceuticals Slides: Q1 2026

May 13, 2026, 4:30 PM EDT - 3 months ago

Inovio Pharmaceuticals Slides: Q1 2026


INOVIO to Participate in Upcoming Scientific Conferences

May 8, 2026, 8:05 AM EDT - 4 months ago

INOVIO to Participate in Upcoming Scientific Conferences


Inovio Pharmaceuticals Proxy statement: Proxy filing

Apr 7, 2026, 8:00 AM EDT - 5 months ago

Inovio Pharmaceuticals Proxy statement: Proxy filing


INOVIO Announces Pricing of $17.5 Million Public Offering

Apr 2, 2026, 8:55 AM EDT - 5 months ago

INOVIO Announces Pricing of $17.5 Million Public Offering


INOVIO to Participate in Upcoming Scientific Conference

Apr 1, 2026, 10:29 AM EDT - 5 months ago

INOVIO to Participate in Upcoming Scientific Conference


Inovio Pharmaceuticals Slides: Corporate presentation

Mar 23, 2026, 8:00 AM EDT - 5 months ago

Inovio Pharmaceuticals Slides: Corporate presentation


Inovio Pharmaceuticals Earnings Call Transcript: Q4 2025

Mar 12, 2026, 4:30 PM EDT - 6 months ago

Inovio Pharmaceuticals Earnings Call Transcript: Q4 2025


Inovio Pharmaceuticals Earnings release: Q4 2025

Mar 12, 2026, 4:30 PM EDT - 6 months ago

Inovio Pharmaceuticals Earnings release: Q4 2025


Inovio Pharmaceuticals Annual report: Q4 2025

Mar 12, 2026, 4:30 PM EDT - 6 months ago

Inovio Pharmaceuticals Annual report: Q4 2025


Inovio Pharmaceuticals Slides: Q4 2025

Mar 12, 2026, 4:30 PM EDT - 6 months ago

Inovio Pharmaceuticals Slides: Q4 2025


INOVIO Reports Inducement Grant Under Inducement Plan

Dec 19, 2025, 4:05 PM EST - 9 months ago

INOVIO Reports Inducement Grant Under Inducement Plan


INOVIO to Participate in December Investor Conferences

Nov 18, 2025, 8:05 AM EST - 10 months ago

INOVIO to Participate in December Investor Conferences


INOVIO Announces Pricing of $25 Million Public Offering

Nov 11, 2025, 8:40 AM EST - 10 months ago

INOVIO Announces Pricing of $25 Million Public Offering


Inovio Pharmaceuticals Earnings Call Transcript: Q3 2025

Nov 10, 2025, 4:30 PM EST - 10 months ago

Inovio Pharmaceuticals Earnings Call Transcript: Q3 2025


Inovio Pharmaceuticals Earnings release: Q3 2025

Nov 10, 2025, 4:30 PM EST - 10 months ago

Inovio Pharmaceuticals Earnings release: Q3 2025


Inovio Pharmaceuticals Quarterly report: Q3 2025

Nov 10, 2025, 4:30 PM EST - 10 months ago

Inovio Pharmaceuticals Quarterly report: Q3 2025


Inovio Pharmaceuticals Slides: Q3 2025

Nov 10, 2025, 4:30 PM EST - 10 months ago

Inovio Pharmaceuticals Slides: Q3 2025


Inovio Pharmaceuticals Earnings Call Transcript: Q2 2025

Aug 12, 2025, 4:30 PM EDT - 1 year ago

Inovio Pharmaceuticals Earnings Call Transcript: Q2 2025


Inovio Pharmaceuticals Earnings release: Q2 2025

Aug 12, 2025, 4:30 PM EDT - 1 year ago

Inovio Pharmaceuticals Earnings release: Q2 2025


Inovio Pharmaceuticals Quarterly report: Q2 2025

Aug 12, 2025, 4:30 PM EDT - 1 year ago

Inovio Pharmaceuticals Quarterly report: Q2 2025


INOVIO to Present at Upcoming Scientific Conference

Jul 7, 2025, 4:05 PM EDT - 1 year ago

INOVIO to Present at Upcoming Scientific Conference


Inovio Pharmaceuticals Slides: Corporate Presentation

Jun 17, 2025, 7:00 AM EDT - 1 year ago

Inovio Pharmaceuticals Slides: Corporate Presentation


Inovio Pharmaceuticals Earnings Call Transcript: Q1 2025

May 13, 2025, 4:30 PM EDT - 1 year ago

Inovio Pharmaceuticals Earnings Call Transcript: Q1 2025


Inovio Pharmaceuticals Earnings release: Q1 2025

May 13, 2025, 4:30 PM EDT - 1 year ago

Inovio Pharmaceuticals Earnings release: Q1 2025


Inovio Pharmaceuticals Quarterly report: Q1 2025

May 13, 2025, 4:30 PM EDT - 1 year ago

Inovio Pharmaceuticals Quarterly report: Q1 2025


INOVIO to Present at Upcoming Scientific Conferences

Apr 9, 2025, 8:05 AM EDT - 1 year ago

INOVIO to Present at Upcoming Scientific Conferences


Inovio Pharmaceuticals Proxy statement: Proxy Filing

Apr 7, 2025, 8:00 AM EDT - 1 year ago

Inovio Pharmaceuticals Proxy statement: Proxy Filing


Inovio Pharmaceuticals Earnings Call Transcript: Q4 2024

Mar 18, 2025, 4:30 PM EDT - 1 year ago

Inovio Pharmaceuticals Earnings Call Transcript: Q4 2024


Inovio Pharmaceuticals Earnings release: Q4 2024

Mar 18, 2025, 4:30 PM EDT - 1 year ago

Inovio Pharmaceuticals Earnings release: Q4 2024


Inovio Pharmaceuticals Annual report: Q4 2024

Mar 18, 2025, 4:30 PM EDT - 1 year ago

Inovio Pharmaceuticals Annual report: Q4 2024


wallstbullinfinity
wallstbullinfinity Aug. 31 at 9:15 AM
$INO collaborations with the Dana-Farber Cancer Institute and Mass General Brigham to evaluate cadonilimab in combination with INOVIO's DNA medicine INO-5412 in glioblastoma (GBM). 🧬🧬🧬🌍🌎🌏 Akeso, Inc | Akeso 2026 Interim Results: Strong Commercialization Momentum; IO2.0+ Global Strategy Redefining Clinical Standards; Bispecific Advancement in ADC, I&I and Alzheimer's https://share.google/v2oC0mQ88fZZlPmO2
0 · Reply
wallstbullinfinity
wallstbullinfinity Aug. 31 at 9:06 AM
$INO HONG KONG, Aug. 27, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced its 2026 interim results. During the reporting period, the Company achieved record-high drug sales revenue Cadonilimab is advancing multi-pathway combination strategies, including combinations with small molecules such as axitinib and tinengotinib in renal and liver cancers, as well as collaborations with the Dana-Farber Cancer Institute and Mass General Brigham to evaluate cadonilimab in combination with INOVIO's DNA medicine INO-5412 in glioblastoma (GBM). Akeso 2026 Interim Results: Strong Commercialization Momentum; IO2.0+ Global Strategy Redefining Clinical Standards; Bispecific Advancement in ADC, I&I and Alzheimer's https://share.google/FmJF1YgA7L2mWCN13
0 · Reply
FZFund
FZFund Aug. 30 at 7:43 PM
$INO if this falls to $1.08 I am going all in!
1 · Reply
updownsides
updownsides Aug. 30 at 7:24 PM
$INO If by some miracle 3107 gets approved, get used to the word "Step Therapy." Probably not an issue until whoever buys them for pennies and does a phase 3 after bankruptcy. https://youtu.be/WYxUrNtLRvw?is=9c7FKwNfc4fKbgLb
0 · Reply
updownsides
updownsides Aug. 30 at 7:08 PM
$INO Buttley the shameless pumper has never given accurate information. The fact he still thinks VGX-3100 will be approved this year when there hasn't been a readout let alone a submission shows his grip on reality is lost. Now it's Geneos. From the 10-Q; As of March 31, 2026 and December 31, 2025, the Company held approximately 9% and 23%, respectively, of the outstanding equity interests of Geneos on an as-converted to common stock basis. The decrease in the Company's ownership interest during the three months ended March 31, 2026 resulted from the issuance of preferred equity securities by Geneos to third-party investors during the first quarter of 2026, in which the Company did not participate. Due to Geneos' continuing net losses, the carrying value of the Company’s investment in Geneos was $0 as of March 31, 2026. N-I-N-E P-E-R-C-E-N-T and not valued anymore in rhe 10-Q!!
0 · Reply
BentleyT99
BentleyT99 Aug. 30 at 4:53 PM
1 · Reply
sunny3
sunny3 Aug. 30 at 11:14 AM
0 · Reply
sunny3
sunny3 Aug. 29 at 12:44 PM
$INO Feel Great
0 · Reply
Whateverbro
Whateverbro Aug. 29 at 1:13 AM
$INO Its running right into resistance on the weekly and on the daily wait for it to break that the more times it try to push up the more chance of a break . Any one know of any up coming news whats the pipeline, why you bullish
3 · Reply
PumperBoatGuy
PumperBoatGuy Aug. 29 at 1:04 AM
$INO ebola keeps spreading into largest ebola outbreak ever. INO has an ebola vaccine sitting on the shelf.
0 · Reply
wallstbullinfinity
wallstbullinfinity Aug. 28 at 11:11 PM
$INO 🧬🧬🧬🌍🌎🌏
0 · Reply
patcarr
patcarr Aug. 28 at 8:09 PM
$INO Nice finish to a quiet day. Litte INO up 5% on the week; half napping, and half creeping. Have a good weekend my friends. From Biblical Times to the Present; although exasperating at times, Goodness has always prevailed. Tune in Monday for another exciting episode: Same PAT Time, same PAT Channel.
1 · Reply
Iluvfor30s
Iluvfor30s Aug. 28 at 5:10 PM
$INO 9 weeks for a CRL. Kennedy is not going to support a DNA medicine...they won't let it move on. Would look bad for him. Their supporters can't understand the benefits of this DNA altering technology that causes mutations and anti-racism. Can't have that.
0 · Reply
PumperBoatGuy
PumperBoatGuy Aug. 28 at 4:46 PM
1 · Reply
CheesyMash
CheesyMash Aug. 28 at 3:57 PM
$INO Don't like getting over that 1.30 does it the bugger come on.
1 · Reply
Jamal1965
Jamal1965 Aug. 28 at 3:11 PM
$INO what's keeping this stock from breaking like a rocket is only one thing it's the management and the number of shares they have.
1 · Reply
BentleyT99
BentleyT99 Aug. 28 at 2:19 PM
$INO Plus dMAb's Which Were Developed With The Wistar Institute......A Game Changer.....AI IT!!!!!!!!!!!!!
1 · Reply
BentleyT99
BentleyT99 Aug. 28 at 2:15 PM
$INO We Got This!!!!!!!!!!!!!!!!!!!
0 · Reply
BKuma29
BKuma29 Aug. 28 at 1:22 PM
$INO 9 weeks for PDUFA. Let’s go DORUXAPAPOGENE RALAPLASMID. We are going to have our moment soon.
1 · Reply
Dew8
Dew8 Aug. 28 at 12:02 PM
$INO 99 percent down for me
1 · Reply
fantastex
fantastex Aug. 28 at 10:59 AM
$INO bought at 0.65 and sold too soon. Good entry now?
1 · Reply
sunny3
sunny3 Aug. 28 at 10:00 AM
1 · Reply